New Treatment Gives Hope For Pulmonary Fibrosis Patients

Patients with idiopathic pulmonary fibrosis may have a new treatment option, according to researchers in Japan. In a Phase III, double-blind, placebo-controlled clinical trial, the investigators discovered that a daily dose of pirfenidone could slow the progression of IPF, reducing the loss of lung capacity.

Read the whole article on Science Daily

More from Science Daily